Q: 54 year old diabetic male is admitted to ICU with mucormycosis. Patient becomes stable after few days of intravenous antifungal therapy, a plan was made to switch to oral posaconazole. Bioavailability for posaconazole is better with? (select one)
A) posaconazole delayed-release tablets
B) oral suspension of posaconazole
The oral suspension of posaconazole is usually not highly bioavailable and requires fatty foods for absorption. Enteral feeding of infected patients in ICU stay variable and so bioavailability of oral suspensions cannot be relied upon.
1. Spanakis EK, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis 2006; 43:1060.
2. Noxafil (posaconazole) injection for intravenous use, delayed-release tablets for oral use, oral suspension, prescribing information. https://www.merck.com/product/usa/pi_circulars/n/noxafil/noxafil_pi.pdf